Key insights
- Merck KGaA's strong earnings and upgraded 2026 outlook, driven by semiconductor demand and Life Science strength, boosted its stock. Positive analyst ratings and a constructive market environment, including hopes for easing US-China trade tensions, further contributed. While primarily a European event, the semiconductor exposure and potential easing of trade tensions offer a slight positive signal for US equities.
Investing.com -- Merck KGaA stock surged +8.8% to trade at €122.9 after the Darmstadt-based science and technology group delivered a first-quarter earnings beat alongside a meaningful upgrade to its full-year 2026 profit outlook.
The company reported a smaller-than-expected decline in Q1 earnings, with the healthcare and electronics giant benefiting from strong demand for its semiconductor offerings, and also slightly raised its guidance for fiscal 2026, citing strength in its Life Science division. Full-year adjusted EBITDA guidance was lifted to €5.7–€6.1 billion, up from the prior range of €5.5–€6.0 billion, thanks to stronger momentum in the Life Science division and delayed competition for the MS drug Mavenclad.
On the earnings detail, net profit fell 9.4% year-on-year to €669 million, or €2.11 per share, beating forecasts of €1.99 per share, while net sales declined 2.8% to €5.13 billion, surpassing estimates of €5.09 billion. The brighter prospects also mark a strong start for new CEO Kai Beckmann, who was promoted from head of the electronics division earlier this month.
On the analyst front, the consensus rating for Merck KGaA stands at "Buy" based on 15 analysts, with 11 recommending a purchase and an average 12-month price target of €143.20. Adding to the positive backdrop, UBS had maintained a Buy rating ahead of the results.
The broader market environment was also constructive. Germany’s DAX rose 0.7% to 24,126 points in early trading, recovering from losses the prior session, while US President Donald Trump’s state visit to China raised market hopes for easing trade tensions between the US and China.
The pan-European STOXX 600 also gained 0.7% as of early Wednesday morning, recovering from a more than 1% decline on Tuesday. Amundi S.A. had also recently increased its stake in Merck KGaA, a signal of growing institutional conviction ahead of the earnings release.
Taken together, the earnings beat, the raised full-year EBITDA guidance, a supportive analyst community, and a recovering German equity market created a powerful confluence of catalysts. Merck KGaA shares led the DAX with the session’s strongest gain after reporting better-than-expected quarterly results, with the stock pushing toward its day high of €123.55 and closing the gap toward its 52-week high of €131.65.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.